CADTH Canadian Drug Expert Committee recommendation (final): Letermovir (Prevymis -- Merck Canada Inc.) indication : cytomegalovirus infection, prophylaxis
The CADTH Canadian Drug Expert Committee (CDEC) recommends that letermovir be reimbursed for the prophylaxis of cytomegalovirus (CMV) infection in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT)
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
CADTH
2018, June 2018
|
Edition: | Version 1.0 |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that letermovir be reimbursed for the prophylaxis of cytomegalovirus (CMV) infection in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT) |
---|---|
Physical Description: | 1 PDF file (7 pages) |